IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Overview of Neuropharmacology

Shelke Jayashree Ashok

Shinde Sayali Pandurang
Students at
Pravara rural college of pharmacy Pravaranagar, Ahmednagar., Maharashtra, India

ABSTRACT :

The study of how medications impact nervous system cellular function is known as neuropharmacology. One must first comprehend how neurons communicate in order to gain a deeper understanding of the foundations of drug creation.(1) with each other. Drugs are being developed by researchers to treat a wide range of neurological conditions, such as pain, psychological disorders, addiction, neurodegenerative illnesses including Parkinson's and Alzheimer's, and many more.(2)(3)Understanding how people behave and think is crucial to appreciating the potential benefits that neuropharmacology may have for medical advancements(3). Behaviour and Thought process are sent between neurons and how drugs can change the molecular underpinnings of these functions.(4) This article will cover both behavioral and molecular neuropharmacology, including how drugs affect key receptors, ion channels, and neurotransmitters and how this helps patients with neurological disorders.(1)

KEYWORDS – Neurological disorder, Threshold potential, Neuromodulator, Behavioural neuropharmacology, Molecular neuropharmacology

INTRODUCTION –

There are two terms associated with neuropharmacology. Pharmacology is the study of medications, while neuro is connected to neurons in the brain. The study of neurotransmitters and neuromodulators and how they affect the brain—particularly the central nervous system— is known as neuropharmacology. (7)Neuropharmacology is a vast field of study that covers a wide range of nervous system functions, from the modification of a single neuron to the involvement of entire regions of the brain, spinal cord, and peripheral nerves.(8) From just 4 approved medications at the beginning, there are currently over 100 medications that neurologists can use in clinical practice.(9) The writer examines the molecular foundation of Neuropharmacology with an emphasis on practical uses. Behavioral and molecular neuropharmacology are the two primary subfields of the field. (10)The study of how medications impact human behavior (neuropsychopharmacology) is the main emphasis of behavioral neuropharmacology. (17)This includes the

Investigation of the effects of drug abuse and addiction on the brain.(16)

3.1.Behavioral neuropharmacology

behavioral neuropharmacology is the study of how drug addiction and reliance affect the human brain. Drug Dependency and Drug Use, Anxiety and Autism .The primary focus of Behavioural Neuropharmacology is how addiction impacts the mind.(16)

Measurements of neural activity with drug misuse. (11)Alcoholism causes tolerance to alcohol, physical dependency, and other symptoms via altering the dopa-mine neurons in the mesolimbic reward system. 17)This area of study usually examines the brain's neurotransmissions and psychological phenomena linked to biological activity.(14(

3.2)Molecular Neuropharmacology-

The study of molecular neuropharmacology, which looks at neurons and their neurochemical connections, is ultimately aimed at developing drugs that enhance brain function. Molecular neuropharmacology, a field that treats neurological disorders by using drugs by Influence the neurochemical interactions between neurons. (16)Researchers are looking into artificial intelligence and other cutting-edge data technologies to try and customize it. 13)A few scientific terminology, such as antagonist, competitive antagonist, and non-competitive antagonist, need to be specified when connecting neurotransmission to receptor function.(14)

HISTORY –

It wasn't until the early 20th century that scientists were able to get a fundamental knowledge of the nervous system and how nerves communicate with one another that the fieldof neuropharmacology emerged. Prior to this finding, several medications had Discovered that showed signs of having an impact on the nervous system. French researchers started experimenting with phenothiazine in the 1930s in an effort to create a medication that may treat malaria.(15)

The research of ion channels and the nerve action potential was made possible by the 1949 introduction of the voltage clamp. (5)These two major historical moments in neuropharmacology allowed researchers to examine not just the transmission of information From one neuron to another and to investigate the internal mechanisms by which a neuron uses this information.(6)

Research in neuropharmacology spans all stages, from in vitro investigations to clinical trials, and it intersects with numerous other disciplines, including cell biology, behavioral neuroscience, and psychiatry.(7) And many, many more, including organic chemistry, computational neuroscience, and biochemistry(8). Perhaps more importantly, though, is that the dictionary definition of neuropharmacology falls short of capturing the energy and enthusiasmof the field as neurological and psychiatric disorders account for an increasing portion of globalresearch funding and the hunt for novel treatments for these illnesses takes center stage.(9)

NEUROPHARMACOLOGICAL CHARACTERISATION AND EVALUATION –

The nervous system is made up of billions of neurons that are connected to one another by axons and dendrites.(10) As seen in Figure 1, there is feed in via axons and turn out via
dendrites. Integrators are the electrical potential of neurons.(11) Medications, as unique chemicals called neurotransmitters, generate chemical signals by means of signal For a medicine to have a therapeutic effect, transduction pathways are triggered on the target cell at the synaptic cleft at threshold potential, similar to the receptors on the target cells. Drugs either release stimulating or inhibiting neurotransmitters(13). A number of medications have been grouped according to their ability to generate neuropharmacological effects on the central nervous system that are medicinally potent.(14)



Figure 1 Schematic diagram of neuron depicting dendrites and axons (6)

In both medicinal chemistry and neurology, the characterisation and identification of targets continue to be key challenges. Advances are facilitated by the new methods in proteomics andgenomes.

NEUROPHARMACOLOGICAL INTERACTION –

Neuropharmacology has great promise for improving human health, but before that can happen, we need to understand how human behavior and thinking processes are passed from one neuron to another and how drugs can change the molecular underpinnings of these processes.(12)

Neurotransmitters interact with two different types of receptors on post-synaptic neurons. The ligand-gated ion channels, or LGICs, are the first class of receptors. The quickest methods of converting a chemical stimulus into an electrical signal are LGIC receptors(17). When a neurotransmitter attaches itself to a receptor, the receptor's structure changes, enabling ions to enter cells directly. G-protein-coupled receptors, or GPCRs, are the second class of receptors.(13)

Synthetic chemicals that function as one of the three above neurotransmitter/receptor connections can alter the following interactions. Action potential inhibitory effects can also be induced by manipulating sodium/potassium ion channels within a neuron.(1,2,5)

1) GABA-In the central nervous system, rapid synaptic inhibition is mediated by the neurotransmitter GABA.(1,4)

The post-synaptic cell will hyperpolarize (remain below its action potential threshold) when GABA is released from its pre-synaptic cell and binds to a receptor, most likely the GABAA receptor. Any excitatory manipulation resulting from other interactions between neurotransmitters and receptors will be offset by this(8)(9).The main target for medication development is this GABAA receptor since it has several binding sites that permit conformational modifications. Benzodiazepine, the most prevalent of these binding sites, permits both agonist.(10)

2)Dopamine - Dopamine binds to five distinct GPCRs in order to mediate synaptic transmission. Two groups of these five receptor proteins are distinguished by whether the Reaction causes the post-synaptic cell to exhibit either an excitatory or inhibitory response. Numerous substances, both legal and illicit, have an impact on dopamine and how it interacts with other chemicals in the brain. Levodopa, a precursor of dopamine, is administered to patients with Parkinson's disease, a condition that lowers dopamine levels in the brain. This isbecause L-dopa can penetrate the blood-brain barrier but dopamine cannot. Additionally, certain Parkinson's patients with restless leg syndrome, or RLS, are prescribed dopamine agonists. Ropinirole and pramipexole are a couple of these (Winkelman et al 2007)(11)

3)Serotonin -

Serotonin, a neurotransmitter, can facilitate synaptic transmission through either GPCRs or receptors for LGICs. (17)The type of receptor expressed in a particular area of the brain determines whether serotonin has excitatory or inhibitory post-synaptic effects. The most well-liked and often prescribed medications for controlling serotonin levels during depression are referred to as selective serotonin reuptake inhibitors, or SSRIs. More serotonin is left in the synaptic gap as
(16)a result of these medications' inhibition of serotonin's transport back into the pre-synapticneuron.(15)

There were medications that blocked the enzyme that breaks down serotonin before SSRIs were discovered. Monoamine oxidase inhibitors, or MAOIs, raised serotonin levels in the synapses but came with a long list of negative effects, such as severe headaches and elevatedblood pressure (16,14)

RECENT ADVANCES –

1) Alzheimer's illness

Although several theories have been put forth to explain the etiology of Alzheimer's disease, our understanding of the condition is still lacking, making it challenging to Create therapeutic strategies. Both neuronal NMDA receptors and nicotinic acetylcholine (nACh) receptors are known to be down-regulated in the brains of
Alzheimer's sufferers. Thus, the U.S. Food and Drug Administration (FDA) has developed and approved four anticholinesterases for use in medical treatment. But given their drawbacks and poor efficacy, these medications are not the best. Nefiracetam is one medication that shows promise for treating Alzheimer's disease and other dementia patients. It works by specifically increasing the activation of nACh receptors as well as NMDA receptors.(18,17)

2)Parkinson's illness

A neurodegenerative condition known as Parkinson's disease is characterized by the selective death of dopaminergic neurons found in the substantia nigra. Currently, the most widely utilized Levodopa, often known as L-DOPA, is a medication used to treat this illness. The neurotransmitter dopamine cannot cross the blood–brain barrier, but this precursor to dopamine may.(13,15)

Whether L-dopa is a superior treatment for Parkinson's disease than other dopamine agonists has been the subject of much research. Long-term L-dopa use is thought by some to impair neuroprotection and ultimately cause the death of dopaminergic cells. Despite the lack of evidence, both in vitro and in vivo, some people continue to think that long-term dopamineagonist treatment is better for patient.(14,16)

3)Cutaneous Nociceptors –

Peripheral receptive ends of primary sensory neurons that are triggered by unpleasant stimuli are known as cutaneous nociceptors. Nociceptor detection and signaling of the presence of stimuli that cause tissue injury. We will concentrate on the molecular mechanisms of cutaneous nociceptors' maintenance, activation, inhibition, and sensitization in this brief overview. During embryogenesis, neurotrophic factors are crucial for the formation of nociceptors. Recent research has shown that either nerve growth factor (NGF) or glial cell line-derived neurotrophic factor (GDNF) maintain adult nociceptors. The natural substance found in capsicum peppers, capsaicin, selectively activates nociceptors. The vanilloid receptor 1 (VR1), the capsaicin receptor, has recently been found, cloned, and characterized.(1,4,6)

Our recent findings provide evidences demonstrate that an activation of both cAMP- and cGMP-second messenger systems is required to induce the sensitization of nociceptors. Such emerging evidences reviewed here would make a significant contribution to further understanding of the molecular mechanism of nociceptor.(1,5,8)

CONCLUSION –

From these review we conclude that neuropharmacology has many advances in recent science. Also how the Behavior and molecular neuropharmacology effective in treatment of neurological disorder. Also from this review we get an idea regarding neuropharmacological interaction and how the different neurotransmitters work.(7,8)

Also we learn there are huge scope of neuropharmacology in various disease like Alzheimer's disease, parkinsonism's and also in cutaneous Nociceptors.(5,7)

REFERENCES-

1.Everitt, B. J.; Robbins, T. W. Neural systems of reinforcement for drug addiction: from Actions to habits to compulsion". Nature Neuroscience, 2005; 8(11): 1481–1489.

2.Wrobel, S. Science, serotonin, and sadness: the biology of antidepressants: A series for The public". The FASEB Journal, 2007 Nov; 21(13):3404-17.

3.Anjula Sachan, Sarvesh Singh, Pratap Shankar*, Rajendra Nath, Amod Kumar Sachan And Rakesh Kumar Dixit Department of Pharmacology & Therapeutics, King George's Medical University, Lucknow, UP, India – 226003.

4.Shin, J. Y.; Park, H. J.; Ahn, Y. H.; Lee, P. H. Neuroprotective effect of l-dopa on Dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study". J Neurochem. 2009 Nov;111(4):1042-50

5.Narahashi, T; Marszalec, W; Moriguchi, S;Yeh,JZ; Zhao, X "Unique mechanism of Action of Alzheimer's drugs on brain nicotinic acetylcholine receptors and NMDA Receptors Life Sci. 2003 Dec 5; 74(2-3):281-91.

6.Brumfitt, S. M., and Peake, M. D. (1988). A double-blind study of verapamil in The treatment of stuttering. Br. J. Disord. Commun. 23, 35–40. Doi: 10.3109/13682828809019875.

7.Burd, L., and Kerbeshian, J. (1991). Stuttering and stimulants. J. Clin. No Psychopharmacol 11, 72–73. Doi: 10.1097/00004714-199102000-00002

8. Masand PS, Ashton A, and Gupta S. et al. Sustained-release bupropion for SSRI-induced sexual dysfunction: a randomized double-blind placebo-controlled, parallel group study. *Am J Psychiatry*. 2001 158:805–807. [PubMed] [Google Scholar]

9.Perlis RH, Fava M, and Nierenberg AA. et al. Strategies for treatment of SSRI-associated sexual dysfunction: a survey of an academic psychopharmacology practice. *Harv Rev Psychiatry*. 2002 10:109–114. [PubMed] [Google Scholar]

10.Solvason HB, DeBattista C, and Kendrick E. et al. Bupropion SR in the treatment of SSRI-induced sexual dysfunction [poster]. Presented at the 40th annual meeting of the New Clinical Drug Evaluation Unit Program (NCDEU). May 30–June 2, 2000 Boca Raton, Fla.

11. Kushal Kumara,b,∗ , Ashwani Kumara , Richard M. Keeganc , Rahul Deshmukha a Neuropharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga 142001, Punjab, India bDefence Institute of High Altitude Research, C/o 56 APO-901205, Leh-Ladakh, India

12. Kalia LV, Lang AE: Parkinson's disease. *Lancet*. 2015;386(9996):896–912. 10.1016/S0140-6736(14)61393-3 [PubMed] [CrossRef] [Google Scholar]

13. Dickson DW: Parkinson's disease and parkinsonism: Neuropathology. *Cold Spring Harb Perspect Med*. 2012;2(8):a009258. 10.1101/cshperspect.a009258 [PMC free article] [PubMed] [CrossRef] [Google Scholar

14. A. Serrano-Pozo, M.P. Frosch, E. Masliah, B.T. Hyman, Neuropathological alterations in Alzheimer disease, Cold Spring Harb. Perspect. Med. 1 (1) (2011) a006189.

15 E. Dawkins, D.H. Small, Insights into the physiological function of the β-amyloid precursor protein: beyond Alzheimer's disease, J. Neurochem. 129 (5) (2014) 756–769.

16 G. Thinakaran, E.H. Koo, Amyloid precursor protein trafficking, processing, and function, J. Biol. Chem. 283 (44) (2008) 29615–29619. [26]

17. K. Spilovska, J. Korabecny, E. Nepovimova, R. Dolezal, E. Mezeiova, O. Soukup, K. Kuca, Multitarget tacrine hybrids with neuroprotective properties to confront Alzheimer’s disease, Curr. Top. Med. Chem. 17 (9) (2017) 1006–1026.

[18] F. Zemek, L. Drtinova, E. Nepovimova, V. Sepsova, J. Korabecny, J. Klimes, K. Kuca, Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine, Expert Opin. Drug Saf. 13 (6) (2014) 759–774.